(Q37141242)

18 August 2017

1 reference

title

Impact of non-alcoholic fatty liver disease on accelerated metabolic complications (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

18 August 2017

0 references

1 reference

based on heuristic

inferred from title

non-alcoholic fatty liver

1 reference

1 reference

Jian Gao Fan

1

1 reference

18 August 2017

publication date

1 May 2008

1 reference

Journal of Digestive Diseases

18 August 2017

published in

1 reference

18 August 2017

volume

9

1 reference

18 August 2017

issue

2

1 reference

18 August 2017

page(s)

63-67

1 reference

GI epidemiology: nonalcoholic fatty liver disease

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

Nonalcoholic fatty liver disease: from steatosis to cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

The metabolic syndrome as a predictor of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

Prevalence of and risk factors for fatty liver in a general population of Shanghai, China

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

Fatty liver and the metabolic syndrome among Shanghai adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

Reduced insulin effect in subclinical fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

Insulin resistance, adiponectin, cytokines in NASH: Which is the best target to treat?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

Liver fat in the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

Interaction of obesity, metabolic syndrome and Framingham risk on steatohepatitis among healthy Taiwanese: population-based nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

Alanine aminotransferase and directly measured insulin sensitivity in a multiethnic cohort: the Insulin Resistance Atherosclerosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

Serial metabolic measurements and conversion to type 2 diabetes in the west of Scotland coronary prevention study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

Persistent elevation of liver function enzymes within the reference range is associated with increased cardiovascular risk in young adults: the Bogalusa Heart Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

Elevations in markers of liver injury and risk of type 2 diabetes: the insulin resistance atherosclerosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

Effects of nonalcoholic fatty liver disease on the development of metabolic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: an open question.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

How should we manage patients with non-alcoholic fatty liver disease in 2007?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

How do we care for children with fatty liver disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1751-2980.2008.00323.X

10.1111/J.1751-2980.2008.00323.X

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference